Did Synta Pharmaceuticals Corp (NASDAQ:SNTA) Find Cure For Cell-Lung Adenocarcinoma

Posted by Steve Raasch October 1, 2013 0 Comment 1650 views

Synta Pharmaceuticals Corp (NASDAQ:SNTA) has announced the presentation of the GALAXY-1 trial results. This is a randomized, global, Phase2b/3 study that was carried out at multiple centers. It has been designed to study patients suffering from advanced non small cell-lung adenocarcinoma. The expectation is that patients suffering from this condition will benefit from ganetespib, the Hsp90 inhibitor’s 2nd-line treatment. Ganetespib is the company’s lead drug candidate.

The planned, interim-analysis had been carried out by the company in May. The results of this analysis are slated to be presented at the ECCO/ESMO/ESTRO 2013 conference. It will include all the interim-findings that had already been presented at the 2013 ASCO. Also included will be the results of 2 of the primary-patient pre-specified studies.

Monday’s trading

In Monday’s trading session, Synta Pharmaceuticals Corp (NASDAQ:SNTA) dropped by 5.54%. The company’s shares opened at a price of $6.63, climbed to an intraday high of $6.64 and dropped to a close of $6.31. Approximately 1.55 million shares were traded on Monday while an average volume of 0.975 million shares were traded over 30 days. The 52-week low of the shares is $3.76 while the 52-week high is $11.88. The company has a market capitalization of $435.76 million.

About the company

Synta Pharmaceuticals Corp (NASDAQ:SNTA) is a bio-pharma company. It focuses on the discovery, development, and commercialization of small-molecule drugs to treat medical conditions of patients suffering from cancer and some inflammatory diseases. As of 31 December 2011, it had 2 drug-candidates in clinical-trials for the treatment of multiple kinds of cancer and numerous drug-candidates that are in preclinical-stages of development.

The company’s discovers and develops its drug candidates internally. For this purpose, it utilizes its chemical-compound library and integrated-discovery engine. In the year ended 31 December 2011, Synta Pharmaceuticals Corp (NASDAQ:SNTA) initiated the Phase 2b/3 clinical trial (GALAXY) of ganetespib in conjunction with docetaxel in treating non-small cell lung cancer.

About Steve Raasch

Steve Raasch is a breaking news reporter for GDP insider. During his nearly two decades of editorial experience, Steve has covered a variety of topics including small business, health, personal finance, advertising, workplace issues and consumer behavior. Steve is very passionate about his work. Steve earned a master of arts degree in international relations from the Johns Hopkins University School of Advanced International Studies in Washington.

View all post by Steve Raasch Visit author's website

Write Your Comment